[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@SentiBio Avatar @SentiBio Senti Biosciences

Senti Biosciences posts on X about $snti, ash, bio, target the most. They currently have XXXXX followers and XX posts still getting attention that total XXX engagements in the last XX hours.

Engagements: XXX #

Engagements Line Chart

Mentions: XX #

Mentions Line Chart

Followers: XXXXX #

Followers Line Chart

CreatorRank: XXXXXXXXX #

CreatorRank Line Chart

Social Influence

Social topic influence $snti #3, ash #1083, bio, target, ceo, hosted

Top accounts mentioned or mentioned by @timlu @aacr @webullglobal @tikcric @nabeeladar @leapsbybayer @cgtinsights @morganstanley @sitcancer @bluerocktx @aliancerms @nasdaq @investorvirtual @insidepm @vjhemonc

Top Social Posts

Top posts by engagements in the last XX hours

"#DidYouSee: We announced new data from our ongoing multinational multicenter clinical trial of SENTI-202 a first-in-class CD33/FLT3 targeting Logic Gated CAR NK cell therapy being studied in patients with relapsed or refractory #AcuteMyeloidLeukemia"
X Link 2025-12-09T14:30Z 2197 followers, XXX engagements

"Were heading to Orlando for the ASH Annual Meeting & Exposition (Dec 69) Excited to connect with the hematology community and share our progress in advancing smarter cell and gene therapies. $SNTI #AML #Oncology"
X Link 2025-12-04T15:46Z 2201 followers, XXX engagements

"#TuneInTomorrow Senti Bio will be hosting a live webcast tomorrow at 8:00 AM ET to discuss updated clinical results from SENTI-202 being presented at the ASH Annual Meeting & Exposition. $SNTI #AML #Oncology"
X Link 2025-12-08T17:00Z 2201 followers, XXX engagements

"Senti Bio Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for SENTI-202 in the Treatment of Adults with Relapsed or Refractory Acute Myeloid Leukemia $SNTI #CellTherapy #Oncology #AML"
X Link 2025-12-09T12:13Z 2201 followers, XXX engagements

"Senti Bio Announces Updated SENTI-202 Clinical Data from Ongoing Phase X Trial in Relapsed or Refractory Acute Myeloid Leukemia Patients Demonstrating Deep MRD Negative Durable Complete Remissions and a Favorable Safety Profile $SNTI #AML"
X Link 2025-12-09T12:15Z 2201 followers, 2261 engagements

"#StartingSoon Senti Bio will be hosting a live webcast beginning at 8:00 AM ET to discuss updated clinical results from SENTI-202 being presented at the ASH Annual Meeting & Exposition. Stay tuned were almost live. $SNTI #AML #Oncology"
X Link 2025-12-09T12:30Z 2201 followers, XXX engagements

"Thank you very much to Dr. Jonathan D. Grinstein for your excellent article in @Inside_PM about how Senti Bio's Logic Gates are transforming the treatment landscape for cancer patients. Learn more here: $SNTI #BloodCancer #AcuteMyeloidLeukemia #R/RAML"
X Link 2025-12-10T14:35Z 2201 followers, XXX engagements

"Dr. Timothy Lu CEO highlighted how Logic Gated cell therapies are designed to precisely target cancer while protecting healthy tissue positioning SENTI-202 as a potentially transformative therapy for AML. Check it out here: $SNTI #ASH2025"
X Link 2025-12-10T15:00Z 2201 followers, XXX engagements

"Our recently delivered oral presentation is now available on our website: Promising results from an ongoing Phase I study of SENTI-202 a first-in-class Logic Gated CD33/FLT3 cell therapy for R/R AML. Access it here: $SNTI #ASH25 #AML #CellTherapy"
X Link 2025-12-10T17:30Z 2201 followers, XXX engagements

"You can now access our ASH poster presentation on our website: Correlative data from the ongoing Phase X study of SENTI-202 showcasing its selective logic-gated design targeting CD33 and/or FLT3 in AML. View it here: $SNTI #CellTherapy #GeneCircuits"
X Link 2025-12-10T19:30Z 2201 followers, XXX engagements

"Senti Bio to Host Conference Call and Webcast to Discuss SENTI-202 Clinical Data Being Presented at the American Society of Hematology (ASH) Annual Meeting 2025 on Tuesday December 9th at 8:00 AM ET $SNTI #CellTherapy #Oncology #AML"
X Link 2025-12-04T14:08Z 2201 followers, XXX engagements

"#InCaseYouMissedIt: We hosted a live webcast sharing updated clinical results from SENTI-202 featured at the ASH Annual Meeting & Exposition. Catch up on the latest data and key insights. Watch the replay: $SNTI #AML #Oncology"
X Link 2025-12-09T15:35Z 2200 followers, XXX engagements

"Dr. Nosha Farhadfar noted that SENTI-202 is demonstrating deep durable responses and a favorable safety profile in R/R AML underscoring its potential to selectively target AML cells while preserving healthy ones. $SNTI #AML #ASH2025"
X Link 2025-12-09T15:05Z 2201 followers, 1552 engagements

"Dr. Farhad Ravandi of MD Anderson Cancer Center discusses our #ASH25 data on @VJHemOnc and why our success targeting CD33 and FLT3 which is expressed highly on AML blasts is so significant in meeting significant unmet needs. Read the story: $SNTI"
X Link 2025-12-11T16:47Z 2201 followers, XXX engagements

"Dr. Kanya Rajangam Chief Medical Officer emphasized that the encouraging SENTI-202 data support advancement into pivotal studies and exploration across additional patient populations enabled by recent RMAT and Orphan Drug Designations. $SNTI #ASH2025"
X Link 2025-12-11T18:55Z 2201 followers, XXX engagements